Mode
Text Size
Log in / Sign up
N/A N=60 Treatment

A Study of BiZact™ on Children and Adolescents Undergoing Tonsillectomy

Tonsillectomy

Enrolled (actual)
60
Serious AEs
0.0%
Results posted
May 2020
Primary outcome: Primary: Intra-operative Blood Loss — 1.7 mL

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
BiZact™: A bipolar instrument for tonsillectomies (Device)
Age
Pediatric · 2+ yrs
Sex
All
Sponsor
Medtronic - MITG
Primary completion
Jun 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Intra-operative Blood Loss
1.7
PRIMARY
Number of Patients With Intra-operative Blood Loss
29; 9; 20
SECONDARY
Number of Cases/Participants Rated Under Different Categories Based on the Performance of the Investigational Device
51; 6; 1; 1; 1
SECONDARY
Number of Cases With Ability to Achieve Hemostasis (Performance of the Investigational Device)
60
SECONDARY
"Number of Cases/Participants With Analgesic Consumption
58; 56; 55; 54; 53; 49
SECONDARY
Post-operative Pain
4.9
SECONDARY
Post-operative Pain
4.9
SECONDARY
Post-operative Pain
4.9
SECONDARY
Post-operative Pain
4.9
SECONDARY
Post-operative Pain
4.9
SECONDARY
Post-operative Pain
4.9
SECONDARY
Post-operative Pain
4.9
SECONDARY
Post-operative Pain
4.9
SECONDARY
Post-operative Pain
4.9
SECONDARY
Post-operative Pain
4.9

Summary

The purpose of this study is to assess safety and performance with the use of the BiZact™ device in tonsillectomy procedures in children and adolescents.

Eligibility Criteria

Inclusion Criteria

  • Children and adolescent subjects 2-12 years of age at the time of the procedure, inclusive
  • Scheduled to undergo tonsillectomy
  • The subject and subject's Legally Authorized Representative (LAR) is willing to participate and consents to participate, as documented by signed informed consent form and/ or assent form (as applicable)

Exclusion Criteria

  • Subjects undergoing:
  • Tonsillectomy as a result of cancer
  • Unilateral tonsillectomy
  • Subjects with:
  • Known Bleeding disorders
  • History of peritonsillar abscess
  • Craniofacial disorders
  • Down's syndrome (Trisomy 21)
  • Cerebral palsy
  • Major heart disease (including but not limited to; right-sided heart failure, left-sided heart failure, congestive heart failure, coronary artery disease, arrhythmias, chronic heart failure, acute heart failure, etc.)
  • Current tobacco use
  • Subjects unable to comply with the required study follow-up visits
  • Female subjects pregnant at time of procedure
  • The subject has comorbidities which, in the opinion of the Investigator, will not be appropriate for the study or the subject has an estimated life expectancy of less than 6 months.
  • The subject is participating or has participated in any drug or device research study within 30 days of enrollment.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03266094). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search